Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical validation of gene targets for dexmedetomidine adverse reactions
ChiCTR2500105507Phase 4Not yet recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine in neurological diseases, sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Primary endpoint: Gene targets associated with dexmedetomidine adverse reactions. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
neurological diseases
Beyond the preview
Go deeper on ChiCTR2500105507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105507.